<SEC-DOCUMENT>0001179022-15-000009.txt : 20150202
<SEC-HEADER>0001179022-15-000009.hdr.sgml : 20150202
<ACCEPTANCE-DATETIME>20150202170457
ACCESSION NUMBER:		0001179022-15-000009
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20150129
FILED AS OF DATE:		20150202
DATE AS OF CHANGE:		20150202

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GALECTIN THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001133416
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043562325
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		STREET 2:		SUITE 240
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071
		BUSINESS PHONE:		678-620-3186

	MAIL ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		STREET 2:		SUITE 240
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRO PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20010612

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			TRABER PETER G
		CENTRAL INDEX KEY:			0001284500

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31791
		FILM NUMBER:		15567848

	MAIL ADDRESS:	
		STREET 1:		430 THAMER LANE
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77025
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>edgar.xml
<DESCRIPTION>PRIMARY DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2015-01-29</periodOfReport>

    <issuer>
        <issuerCik>0001133416</issuerCik>
        <issuerName>GALECTIN THERAPEUTICS INC</issuerName>
        <issuerTradingSymbol>GALT</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001284500</rptOwnerCik>
            <rptOwnerName>TRABER PETER G</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O GALECTIN THERAPEUTICS INC.</rptOwnerStreet1>
            <rptOwnerStreet2>4960 PEACHTREE INDUSTRIAL BLVD., STE 240</rptOwnerStreet2>
            <rptOwnerCity>NORCROSS</rptOwnerCity>
            <rptOwnerState>GA</rptOwnerState>
            <rptOwnerZipCode>30071</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>President &amp; CEO</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>3.45</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2015-01-29</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>134000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2025-01-29</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>134000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>134000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The options vest as follows: 25% immediately,  and  the remaining 75% in equal installments on a monthly basis  over a period of three years.</footnote>
    </footnotes>

    <remarks>Exhibit Index:
Exhibit 24 - Power of Attorney</remarks>

    <ownerSignature>
        <signatureName>Jack W. Callicutt, by power of attorney</signatureName>
        <signatureDate>2015-02-02</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>traberpoa.htm
<DESCRIPTION>POWER OF ATTORNEY
<TEXT>
<html>

<head>
<title>Power of Attorney</title>
</head>

<body>

<b>
<p ALIGN="CENTER">CONFIRMING STATEMENT</p>
</b>
<p>This statement confirms that the undersigned has authorized and designated
the Chief Executive Officer, the Chief Financial Officer or the Chief Operating
Officer of Galectin Therapeutics Inc. (the &quot;Company&quot;) to execute and file on the
undersigned's behalf all Forms 3, 4 and 5 (including any amendments thereto)
that the undersigned may be required to file with the U.S. Securities and
Exchange Commission as a result of the undersigned's ownership of or
transactions in securities of the Company.&nbsp; The authority of the Chief
Executive Officer, the Chief Financial Officer or the Chief Operating Officer of
the Company under this Statement shall continue until the undersigned is no
longer required to file Forms 3, 4 and 5 with regard to the undersigned's
ownership of or transactions in securities of the Company unless earlier revoked
in writing.&nbsp; The undersigned acknowledges that the Chief Executive Officer,
the Chief Financial Officer or the Chief Operating Officer of the Company is not
assuming any of the undersigned's responsibilities to comply with Section 16 of
the Securities Exchange Act of 1934.</p>
<p>&nbsp;</p>
<p ALIGN="CENTER"></p>
<center>
<table CELLSPACING="0" BORDER="0" style="border-collapse: collapse" bordercolor="#111111" cellpadding="0" width="900">
  <tr>
    <td WIDTH="50%" VALIGN="TOP" HEIGHT="45">Dated as of June 24, 2013</td>
    <td WIDTH="50%" VALIGN="TOP" HEIGHT="45">&nbsp;<p><u>/s/ Peter G. Traber&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <br>
    </u>Name:&nbsp; Peter G. Traber</td>
  </tr>
</table>
</center>
<p></p>
<p>&nbsp;</p>

</body>

</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
